Related Experiment Video
Updated: Mar 17, 2026

05:38
The Effect of Anti-Fatigue Decoction on the Behaviors and Serological Indicators in a Central Fatigue Rat Model
Published on: April 12, 2024
629
[Therapy of fatigue in multiple sclerosis : A treatment algorithm]
C Veauthier1,2, F Paul3,4
1Interdisziplinäres Schlafmedizinisches Zentrum, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland. christian.veauthier@charite.de.
Der Nervenarzt
|July 23, 2016
Summary
Multiple sclerosis (MS) fatigue is common and impacts employment. Ruling out other conditions and addressing sleep disorders are key, as effective medications are limited.
Area of Science:
- Neurology
- Sleep Medicine
Background:
- Fatigue is a primary symptom of multiple sclerosis (MS), significantly impacting patients' quality of life and employment.
- The underlying mechanisms of MS-related fatigue remain unclear, with comorbid conditions playing a crucial role.
Purpose of the Study:
- To present current treatment strategies for MS-related fatigue.
- To specifically focus on managing fatigue secondary to sleep disorders in MS patients.
Main Methods:
- A comprehensive literature review was conducted to synthesize existing research on MS fatigue treatments.
Main Results:
- Excessive daytime sleepiness (EDS) must be assessed in MS patients with fatigue, as sleep disorders are common causes.
- Medications (e.g., antihistamines), anemia, iron deficiency, diabetes, and hypothyroidism can exacerbate MS fatigue.
- Cognitive behavioral therapy, exercise, physiotherapy, and fatigue management interventions show promise in improving MS fatigue.
Conclusions:
- Thorough evaluation for sleep disorders, including EDS, is essential for MS patients experiencing fatigue.
- Excluding comorbid conditions and optimizing medication regimens are critical steps in managing MS fatigue.
- While pharmacological options are scarce, non-pharmacological interventions offer significant potential for improving fatigue in multiple sclerosis.
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
3.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.3K
Muscle Recovery and Fatigue
4.7K
Muscle fatigue refers to the decline in a muscle's ability to maintain the force of contraction after prolonged activity. It primarily stems from changes within muscle fibers. Even before experiencing muscle fatigue, one may feel tired and have the urge to stop the activity. This response, known as central fatigue, occurs due to changes in the central nervous system, namely the brain and spinal cord. While there is no single mechanism that induces fatigue, it may serve as a protective...
4.7K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K

